The State of Despair Among Many NIH Grantees

I am on a flight returning from a trip to Washington DC. I was visiting friends and former colleagues from my days at NIH. Several of my friends are now running research labs at medical centers, one of whom has served on several study sections. Another former colleague has gone on to become a Program Officer at NIH. One person does public health education at NIH, and another is running a successful freelance business. Each of them was interested in discussing the state of NIH grantwriting, especially given that the preliminary summary statements from the previous grant cycle have just become available on eCommons. We are all disturbed by the pervasive feeling of despair that I hear among NIH grantees.

One concern I hear repeatedly from both grantees and NIH program staff is concern about the quality of the review process on study sections. There are those who feel that regardless of the quality of the proposal, the best scores tend to go to the big-name labs who already are flush with funding. (I have heard it suggested by more than one person that reviews would work better if proposals were submitted anonymously.) Some feel that while New and Early Stage Investigators are given better opportunities to obtain funding, mid-career researchers are left in the cold because of the tendency to dole out money for the big-name labs. Another concern I often hear is that there are “cliques” within a given field, and the power to award great scores rests in the hands of the “in group” in a study section, while those outside the clique remain unscored and unfunded. I sometimes hear grantees and even program staff at NIH complain that the Summary Statements are illogical or contradictory– or worse, unintelligent. (When I see Summary Statements that are illogical or contradictory, often it is because the grant was confusing. Poor writing is not always the cause of such reviewer responses. But you can decrease your odds of a confused or ill-informed reviewer by writing more clearly and concisely.)

Almost certainly, there is some element of truth to each of these concerns. But I hate to see such talk discourage promising researchers from entering or remaining in the field. One could speculate endlessly about how to game the system when it comes to NIH grantsmanship. I think a great deal of such speculation is wasted energy. I hear a lot of stories from people in the field about what has gone wrong with their career, their proposals, the myriad ways in which they have been screwed. Being a proposal writer is a bit like being a bartender at times. And I see grantees making a lot of poor choices that are directly within their control to change. Here are some suggestions based on the mistakes I see:

When it comes to interacting with your colleagues, do your level best not to make enemies. Areas of biomedical research expertise have become so narrow and esoteric that you cannot afford to antagonize anyone in the handful of researchers in your field. That said, given the level of desperation over the current funding climate, you probably also should play your cards close to the vest. Be careful with whom you discuss your ideas. Your draft Aims may be best discussed at departmental chalk talks, where you can elicit great feedback while also divulging your ideas to a larger group who may serve as witnesses later on that the ideas were indeed yours. (Yes, I hear lots of talk of researchers stealing each other’s ideas.) Be assertive. It pays to ask for everything and anything you need, as the worst you will hear is no. I have a client who requested funds for proposal writing support from everyone—her Chair, the Dean, anyone who would listen. She got a little money from each source that, together with a little money from her start-up, helped pay for help on a K01 and a Robert Wood Johnson proposal (she landed both.) Her colleagues have whined about the help she has gotten, and why haven’t they been offered such help? (The answer: They never asked.) More examples: If you have done the work, insist on being first or last author on the manuscript. Conversely, if you are not the PI on a grant, do not do all the work. You will get no recognition. Above all, behave with integrity– even when your colleagues do not.

I have a great deal of respect for researchers who remain in the trenches of biomedical research, continuing to apply for grants even in the current funding climate. Such work is much more difficult than what I do. Increasingly, medical research facilities are shifting toward the elimination of tenure while demanding that their faculty rely 100% on soft money. It is not for the faint of heart.

But if you choose to remain, you must work to develop an extraordinarily thick skin. Proposal writing is an iterative process. With each submission, you use the Summary Statements to hone your grantsmanship. You work to find a great Program Officer in an institute that is a good fit for your work, and then you work with the PO to figure out how to tailor your research to fit the funding priorities and interests of the institute. If you are suspect of the quality of your study section, shift your focus and request a different one. There is little use in dwelling on your fears (real or not) about the inequities and injustices in the review process, at least not while you are putting together a proposal submission. Your energy is best spent on improving your proposal and your grantsmanship on that submission, to the best of your ability.

The NIH FY12 Appropriation: What Do We Know So Far?

Now that we finally know (more or less) what the budget situation will be for the remainder of FY11, we must turn our attention to the odious task of following the FY12 appropriation saga as it unfolds. Where do we stand so far on the FY12 Appropriation Bill?

NIH has requested $31.987B for FY12. Last February, the Administration endorsed that request, recommending $31.829B  for the agency. (For those keeping score at home, the Administration’s FY12 request for NSF was $7.424B and for DOE’s Office of Science they recommended $5.4B.) The Administration’s NIH request is 3.4% over the FY10 enacted level, though when adjusted for inflation that amount represents approximately level funding.

Earlier this month, the Republican-controlled House of Representatives released their version of the FY12 budget, which bears not even a fleeting resemblance to the one proposed by the Administration. Their budget includes drastic cuts across the board, including to the Department of Defense, as Republicans begin to craft their message of financial restraint for the 2012 Presidential election. Their goal is to cut discretionary spending to pre-2008 levels and freeze it there for five years, as they seek to tackle the alarming federal budget deficit (there are 12 zeros in $15 trillion, in case you were wondering). The Democratic Senate and the Administration are almost certain to reject the austere proposal, thus setting the stage for another budget drama in which the two chambers of Congress cannot come to agreement on the FY12 Appropriations bill. For an excellent overview of the House FY12 budget proposal, click here.